Effectiveness of finerenone in Chinese patients with type 2 diabetes mellitus and chronic kidney disease with microalbuminuria: A retrospective real‐world study

Abstract

ABSTRACT Aim No studies have specifically examined the effects of finerenone in treating type 2 diabetes patients with chronic kidney disease (CKD) and microalbuminuria. This study aimed to evaluate the effectiveness of finerenone in this group of patients. Methods This retrospective real‐world study (ChiCTR2400087169) included type 2 diabetes outpatients with CKD from the Peking University First Hospital between March 2023 and March 2024. All patients in this study had a urinary albumin‐to‐creatinine ratio (UACR) of 30–299 mg/g. The effects of finerenone were assessed by comparing UACR, HbA1c, creatinine, serum potassium, eGFR, and blood pressure at baseline and after treatment. Results Sixty‐four patients (39 males and 25 females), with a median age of 65.75 years and a median duration of T2DM of 15.21 years, were included. The baseline median UACR was 100.50 mg/g, significantly decreased to 61.27 mg/g (P 30% UACR decrease had significantly higher baseline systolic blood pressure (SBP) than those with a ≤30% decrease (P 30% UACR reduction (P < 0.05). Conclusions Finerenone is effective in treating type 2 diabetes with CKD and microalbuminuria. Improved SBP control leads to a greater UACR reduction.

Keywords

• Diabetes mellitus, type 2
• Finerenone
• Microalbuminuria